Amarantus to Present at LD Micro and The
Reg A Conference
New York, NY -- May 24,
2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings,
Inc. (OTC
Pink: AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus
biotechnology holding company, developing first-in-class orphan
neurologic, regenerative medicine and ophthalmic therapies and
diagnostics through its subsidiaries, today announced that its
President & CEO Gerald Commissiong will be presenting a
corporate overview at the 8th Annual LD Micro Invitational on June
5th, 2018 at 4:30pm PT and at The Reg A Conference on June 12th,
2018 at 3:45pm ET. Management will be available to meet with
interested parties 1 on 1 throughout both events.
Presentation
Details
Event: 8th Annual LD
Micro Invitation
Date: Tuesday, June
5, 2018
Time: 4:30 p.m.
Pacific Time / 7:30 p.m. Eastern Time
Location: Luxe Sunset
Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049
Website: https://www.ldmicro.com/events
Event: The Reg A
Conference
Date: Tuesday, June
12, 2018
Time: 3:45 p.m
Eastern Time / 12:45pm Pacific Time
Location: TKP New
York Conference Center, 109 West 39th Street, New York, NY
10018
Website: https://theregaconference.com
About Amarantus
Bioscience Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS) is a JLABS alumnus biotechnology company developing
treatments and diagnostics for diseases in the areas of neurology,
regenerative medicine and orphan diseases through its subsidiaries.
AMBS' wholly-owned subsidiary Elto Pharma, Inc. has
development rights to eltoprazine, a Phase 2b-ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia,
Alzheimer's aggression and adult attention deficit hyperactivity
disorder, commonly known as ADHD. AMBS acquired the rights to the
Engineered Skin Substitute program, a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen Corporation. AMBS'
wholly-owned subsidiary MANF Therapeutics, Inc. owns key
intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics, Inc.
is developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
The Company also re-acquired rights to the Alzheimer's blood
diagnostic LymPro Test , MSPrecise and NuroPro.
For further information
please visit www.Amarantus.com, or connect with the Amarantus on Facebook,LinkedIn,Twitterand Google+.
Amarantus
Investor and Media Contact:
Howard
Gostfrand
American Capital Ventures,
Inc.
Office:
305-918-7000
Email: hg@amcapventures.com
Source: Amarantus
Bioscience Holdings, Inc.